Successful Management of Crizotinib-Induced Neutropenia in a Patient with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer: A Case Report |
| |
| Authors: | Jun Osugi Yuki Owada Takumi Yamaura Satoshi Muto Naoyuki Okabe Yuki Matsumura Mitsunori Higuchi Hiroyuki Suzuki Mitsukazu Gotoh |
| |
| Institution: | Department of Regenerative Surgery, Fukushima Medical University, School of Medicine, Fukushima, Japan |
| |
| Abstract: | Crizotinib, the first clinically available inhibitor of anaplastic lymphoma kinase (ALK) gene rearrangement, is generally well tolerated. In contrast, neutropenia induced by crizotinib is a commonly reported grade 3 or 4 adverse event. In such cases, interruption and dose reduction of crizotinib might be necessary for some patients with severe neutropenia. However, information concerning clinical experience and management of severe neutropenia is currently limited. In this report, the successful management of crizotinib-induced neutropenia by dose reduction of crizotinib in a patient with ALK-positive non-small cell lung cancer is described.Key Words: Crizotinib, Anaplastic lymphoma kinase gene rearrangement, Neutropenia, Alectinib, Non-small cell lung cancer |
| |
| Keywords: | |
|
|
